ACRBP and ovarian cancer: As such, depletion of ACRBP in ovarian cancer cells treated with paclitaxel resulted in elevated NuMa levels, activating the spindle assembly checkpoint response, and leading to mitotic delay, mitotic catastrophe and subsequently enhanced treatment response.